ABT

Abbott Laboratories
D

ABT

Arincen83/100B
115.550
USD
6.14
(5.61%)
Post Trading·115.230USD-0.320(-0.28%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 1.64Revenue estimate 13.22B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

Abbott Laboratories revenue 1985–2026

Abbott Laboratories's revenue in Q3 FY2026, the three months to 30 September 2026, was 13.01B USD, up 14.5% on the same quarter a year before. Abbott Laboratories's revenue over the last twelve months was 48.23B USD, up 10.0% on the twelve months before. In fiscal year 2025 it was 44.33B USD, up 5.7% on the year before.

Last updated 3 Nov 2026 · Next report 28 Jan 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202648.23B+10.00%27.55B4.70B
FY202531 Dec 202544.33B+5.67%24.61B6.52B
FY202431 Dec 202441.95B+4.59%21.33B13.40B
FY202331 Dec 202340.11B-8.12%20.04B5.72B
FY202231 Dec 202243.65B+1.34%22.32B6.93B
FY202131 Dec 202143.08B+24.47%23.21B7.07B
FY202031 Dec 202034.61B+8.48%17.38B4.50B
FY201931 Dec 201931.90B+4.34%16.69B3.69B
FY201831 Dec 201830.58B+11.64%15.82B2.37B
FY201731 Dec 201727.39B+31.35%13.07B477.00M
FY201631 Dec 201620.85B+2.20%11.24B1.40B
FY201531 Dec 201520.41B+0.78%10.96B4.42B
FY201431 Dec 201420.25B-7.33%10.49B2.28B
FY201331 Dec 201321.85B-45.21%9.86B2.58B
FY201231 Dec 201239.87B+2.63%10.85B5.96B
FY201131 Dec 201138.85B+10.48%23.44B4.73B
FY201031 Dec 201035.17B+14.31%20.59B4.63B
FY200931 Dec 200930.77B+4.19%17.62B5.75B
FY200831 Dec 200829.53B+13.94%17.04B4.88B
FY200731 Dec 200725.91B+15.30%14.59B3.61B
FY200631 Dec 200622.48B+0.62%12.84B1.72B
FY200531 Dec 200522.34B+13.51%11.87B3.37B
FY200431 Dec 200419.68B-0.00%10.80B3.24B
FY200331 Dec 200319.68B+11.29%10.21B2.75B
FY200231 Dec 200217.68B+8.59%9.18B2.79B
FY200131 Dec 200116.29B+18.47%8.54B1.55B
FY200031 Dec 200013.75B+4.31%7.51B2.79B
FY199931 Dec 199913.18B+5.61%7.20B2.45B
FY199831 Dec 199812.48B+5.00%7.08B2.33B
FY199731 Dec 199711.88B+7.90%6.84B2.08B
FY199631 Dec 199611.01B+10.00%6.28B1.88B
FY199531 Dec 199510.01B+9.35%5.69B1.69B
FY199431 Dec 19949.16B+8.90%5.16B1.52B
FY199331 Dec 19938.41B+7.08%4.72B1.40B
FY199231 Dec 19927.85B+14.18%4.77B1.24B
FY199131 Dec 19916.88B+11.66%4.12B1.09B
FY199031 Dec 19906.16B+14.48%3.60B965.80M
FY198931 Dec 19895.38B+8.97%3.13B859.80M
FY198831 Dec 19884.94B+12.51%2.85B752.00M
FY198731 Dec 19874.39B+15.24%2.53B632.60M
FY198631 Dec 19863.81B+13.31%2.14B540.50M
FY198531 Dec 19853.36B—1.82B465.30M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Abbott Laboratories revenue growth by segment

Q2 FY2026 against Q2 FY2025

Medical Devices5.85B
+9.0%
Diagnostic Products3.09B
-47.6%
Nutritional Products2.14B
-3.1%
Established Pharmaceutical Products1.50B
+8.4%
Other5.00M
—

Abbott Laboratories revenue by segment over time

Medical Devices Diagnostic Products Nutritional Products Established Pharmaceutical Products Vascular Products Unallocated Amount to
Fiscal yearMedical DevicesDiagnostic ProductsNutritional ProductsEstablished Pharmaceutical ProductsVascular ProductsUnallocated Amount to
FY202521.39B +12.6%8.94B -4.3%8.45B +0.5%5.54B +6.6%— —
FY202418.99B +12.4%9.34B -6.5%8.41B +3.2%5.19B +2.5%— —
FY202316.89B +15.0%9.99B -39.8%8.15B +9.3%5.07B +3.1%— —
FY202214.69B +2.2%16.58B +6.0%7.46B -10.1%4.91B +4.1%— —
FY202114.37B +21.9%15.64B +44.8%8.29B +8.5%4.72B +9.6%— —
FY202011.79B -3.7%10.81B +40.1%7.65B +3.2%4.30B -4.1%— 66.00M +15.8%
FY201912.24B +29.7%7.71B +2.9%7.41B +2.5%4.49B +1.4%— 57.00M -97.1%
FY20189.44B +5.9%7.50B +33.5%7.23B +4.4%4.42B +3.1%— 2.00B +20.8%
FY20178.91B 5.62B +16.7%6.93B +0.4%4.29B +11.1%— 1.65B -30.8%
FY2016— 4.81B +3.6%6.90B -1.1%3.86B +3.7%2.90B +3.7%2.39B +5.0%

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Abbott Laboratories's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.